{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:39:35Z","timestamp":1765294775164},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00277-016-2631-0","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:16:26Z","timestamp":1457568986000},"page":"733-738","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy"],"prefix":"10.1007","volume":"95","author":[{"given":"Caitlin","family":"O\u2019Neill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell K.","family":"Brynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vergara-Lluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Moschiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"issue":"8","key":"2631_CR1","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065\u20133072. doi: 10.1182\/blood-2008-03-143537","journal-title":"Blood"},{"issue":"32","key":"2631_CR2","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol: Off J Am Soc Clin Oncol 27(32):5418\u20135424. doi: 10.1200\/JCO.2009.23.6075","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"24","key":"2631_CR3","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","volume":"117","author":"RT Silver","year":"2011","unstructured":"Silver RT, Vandris K, Goldman JJ (2011) Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117(24):6669\u20136672. doi: 10.1182\/blood-2010-11-320069","journal-title":"Blood"},{"key":"2631_CR4","author":"M Pizzi","year":"2015","unstructured":"Pizzi M, Silver RT, Barel A, Orazi A (2015) Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Modern Pathol: Off J US Canadian Acad Pathol Inc. doi: 10.1038\/modpathol.2015.93","journal-title":"Modern Pathol: Off J US Canadian Acad Pathol Inc"},{"issue":"6","key":"2631_CR5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","volume":"162","author":"JC Ianotto","year":"2013","unstructured":"Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ (2013) Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 162(6):783\u2013791. doi: 10.1111\/bjh.12459","journal-title":"Br J Haematol"},{"issue":"7240","key":"2631_CR6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MA Essers","year":"2009","unstructured":"Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458(7240):904\u2013908. doi: 10.1038\/nature07815","journal-title":"Nature"},{"issue":"1","key":"2631_CR7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI117333","volume":"94","author":"RWE Bhatia","year":"1994","unstructured":"Bhatia RWE, McGlave PB, Verfaillie CM (1994) Interferon-\u03b1 restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta1 integrin receptor function. J Clin Invest 94(1):384\u2013391","journal-title":"J Clin Invest"},{"issue":"1","key":"2631_CR8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2010.09.006","volume":"53","author":"HMT Moll","year":"2011","unstructured":"Moll HMT, Zommer A, Lavoie T, Brostjan (2011) The differential activity of interferon-\u03b1 subtypes is consistent among distinct target genes and cell types. Cytokine 53(1):52\u201359","journal-title":"Cytokine"},{"issue":"6","key":"2631_CR9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1600-0609.2010.01531.x","volume":"85","author":"M Tarnowski","year":"2010","unstructured":"Tarnowski M, Liu R, Wysoczynski M, Ratajczak J, Kucia M, Ratajczak MZ (2010) CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur J Haematol 85(6):472\u2013483. doi: 10.1111\/j.1600-0609.2010.01531.x","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2631-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2631-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2631-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:50:05Z","timestamp":1559037005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2631-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2631"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2631-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}